UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 03, 2025 |
Perspective Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-33407 |
41-1458152 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320 |
|
|||
Seattle, Washington |
|
98121 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (206) 676-0900 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
Common Stock, $0.001 par value |
|
CATX |
|
NYSE American LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On March 3, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PERSPECTIVE THERAPEUTICS, INC. |
|
|
|
|
Date: |
March 4, 2025 |
By: |
/s/ Juan Graham |
|
|
|
Juan Graham, Chief Financial Officer |
Corporate Presentation
Developing the Next Generation of Targeted Therapies
Radiopharmaceutical Therapy Poised to Revolutionize Oncology TreatmentPerspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT
Perspective’s Innovative Platform
Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window
Proposed Mechanism of Action for 212Pb
Perspective’s Proprietary Chelator Has Been Optimized for Lead-Based RPTs
Perspective’s Pre-Targeting Platform
Supply Chain and Manufacturing Infrastructure
On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products
Neuroendocrine Tumors: VMT-⍺-NET
Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors
Anti-Tumor Activity
Signal of Sustained Anti-Tumor Activity
[212Pb]VMT-α-NET Was Well Tolerated
No Decline in Renal Function Observed
Patient with PR after [212Pb]VMT-α-NET
Melanoma Program: VMT01/02
Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma
Treatment Emergent Adverse Events (occurring in ≥ 2 patients and/or Grade ≥ 2)
PSV359 is Active Against FAP-α Expression on Tumor and on Stroma
General Corporate Information
Abbreviations